MEDI-528: Completed Phase IIb enrollment

Ligand disclosed in its 4Q10 earnings that AstraZeneca's MedImmune LLC unit completed enrollment of 320 patients in an open-label, placebo-controlled Phase IIb trial evaluating 30, 100 and 300 mg sub...